R&D and Medical Affairs Careers
Concentrated resources strengthen our presence in the pharmaceutical market and help us meet highly competitive goals, further enhancing Eisai’s commitment as a human health care (hhc) company.
An innovative end-to-end business model efficiently integrates discovery, clinical and commercial functions to support our unmatched pipeline in neuroscience oncology, and antibody-based programs. Forward-thinking candidates who are dedicated to advancing patient care have the opportunity to embark on diverse and expansive career paths in these areas:
Eisai’s efforts are centered on dementia prevention and cure via the next-generation Alzheimer’s disease treatments now under development. We are also pursuing a new insomnia treatment, as well as expanded indications and new formulations for existing products. Current neurology R&D initiatives include:
- Early and Minimally Invasive Diagnostics
- Novel Neuro-Transmission Pathways
- Neuro Inflammation and Immuno-Genetics
- Synapse Micro-Environment
- Neuronal Regeneration
The brain is thought of as the last frontier in medical research, and Eisai is at the forefront of creating innovative medications in this area. Everybody has a chance to become a true innovator at Eisai and ultimately work toward helping the growing number of patients suffering from neurodegenerative diseases across the world.
Teiji Kimura Ph.D. Chief Discovery Officer Neurology Business Group.
We are currently exploring more than one dozen molecules, formulations, and combinations in 20+ clinical trials. Current oncology R&D initiatives include:
- Mesenchymal Cells and Stromal Cells (Cell Differentiation and Cancer Stemness)
- Myeloid Cells (Immunosuppressive Myeloid Lineage)
- Endothelial Cells (Abnormal Tumor Vessels)
Cancer Cells – Driver Gene Mutation and Aberrant Splicing
One of the things that makes Eisai Oncology different is that most of the anticancer agents in our portfolio come from our own prolific research laboratories, which means that we are able to seamlessly integrate our mechanistic, clinical, and commercial know-how throughout the whole life cycle of the agent.
Ivan Cheung Chairman Eisai Inc.Global President, Neurology Business Group
Eisai Center for Genetics Guided Dementia Discovery (G2D2)
The Eisai Center for Genetics Guided Dementia Discovery (G2D2) is an exploratory research facility in Cambridge, MA, that seeks to leverage the power of human genetics, data sciences and precision chemistry to develop compounds to treat Alzheimer’s disease (AD) and other dementias.
At G2D2, our diverse group of passionate, dedicated and collaborative scientists not only focus on how data can help identify and validate therapeutic targets, but also how it guides novel approaches to drug targets and aims to match them to the right patient at the right time.
Through its four research segments (Data Sciences, Discovery Sciences, Precision Chemistry and Immunodementia*), the team at G2D2 is uniquely positioned to deliver tailor-designed small molecules, anti-sense oligo-nucleotides, and other solutions for targeted therapeutics.
Following through on our entrepreneurial mindset, G2D2 established the Eisai Incubator for NeuroDiscovery, which provides space to Cambridge-based start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics.
*Immunodementia is a novel genetically validated target modulating immune mechanism that treats dementia.